帕金森病冲动控制障碍与左旋多巴诱导的运动障碍:研究更新
本文综述帕金森病中多巴胺能药物相关的运动与非运动行为副作用,包括运动障碍和冲动控制障碍。左旋多巴诱导的运动障碍在慢性治疗数年后发生率高达80%,而多巴胺受体激动剂相关冲动控制障碍约17%。研究提示这些行为反映药物与个体易感性及帕金森病神经生物学的交互作用。
要点
- 左旋多巴诱导的运动障碍在慢性治疗数年后发生率高达80%。
- 多巴胺受体激动剂相关冲动控制障碍发生率约17%。
- 冲动控制障碍亚型有可分离的神经相关物,提示个体易感性差异。
核心结论
- 帕金森病中多巴胺能药物相关的运动障碍和冲动控制障碍反映药物与个体易感性及疾病神经生物学的交互作用。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- 左旋多巴诱导的运动障碍在慢性治疗数年后发生于高达80%的帕金森病患者。
- 冲动控制障碍(包括赌博障碍、暴食障碍、强迫性性行为和强迫性购物)在多巴胺受体激动剂治疗的帕金森病患者中发生率约17%。
- 帕金森病动物模型显示慢性多巴胺能药物增强强化效应,并提示个体易感性的潜在作用。
- 帕金森病合并冲动控制障碍患者在决策冲动性各亚型中均存在损害,可能反映不确定性和奖赏与损失的相对平衡。
- 冲动控制障碍亚型具有可分离的相关物,提示个体易感性 predisposes 不同行为亚型和神经生物学基质的表达。
关键数值与推荐
- 左旋多巴诱导的运动障碍发生率:高达80%(慢性治疗数年后)。
- 冲动控制障碍发生率:约17%(多巴胺受体激动剂治疗的帕金森病患者)。
临床怎么用
- 临床应监测帕金森病患者多巴胺能药物相关的运动障碍和冲动控制障碍。
- 针对冲动控制障碍的治疗干预在随机对照试验中已显示疗效。
局限性
- 需要大规模研究以识别个体风险因素和新的治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dopaminergic medications used in the treatment of patients with Parkinson's disease are associated with motor and non-motor behavioural side-effects, such as dyskinesias and impulse control disorders also known as behavioural addictions. Levodopa-induced dyskinesias occur in up to 80% of patients with Parkinson's after a few years of chronic treatment. Impulse control disorders, including gambling disorder, binge eating disorder, compulsive sexual behaviour, and compulsive shopping occur in about 17% of patients with Parkinson's disease on dopamine agonists. These behaviours reflect the interactions of the dopaminergic medications with the individual's susceptibility, and the underlying neurobiology of Parkinson's disease. Parkinsonian rodent models show enhanced reinforcing effects of chronic dopaminergic medication, and a potential role for individual susceptibility. In patients with Parkinson's disease and impulse control disorders, impairments are observed across subtypes of decisional impulsivity, possibly reflecting uncertainty and the relative balance of rewards and losses. Impairments appear to be more specific to decisional than motor impulsivity, which might reflect differences in ventral and dorsal striatal engagement. Emerging evidence suggests impulse control disorder subtypes have dissociable correlates, which indicate that individual susceptibility predisposes towards the expression of different behavioural subtypes and neurobiological substrates. Therapeutic interventions to treat patients with Parkinson's disease and impulse control disorders have shown efficacy in randomised controlled trials. Large-scale studies are warranted to identify individual risk factors and novel therapeutic targets for these diseases. Mechanisms underlying impulse control disorders and dyskinesias could provide crucial insights into other behavioural symptoms in Parkinson's disease and addictions in the general population.
引用
- Voon V, Napier TC, Frank MJ, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. Lancet Neurol. 2017. PMID: 28229895. doi:10.1016/S1474-4422(17)30004-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。